|
|
 |
|
Viewing report
|
|
|
|
DrugPatentWatch Basic Plan
thinkBiotech LLC, May 2012
DrugPatentWatch provides information on drug patents and their expirations. Datasets include Paragraph IV challenges, tentative approval (an indicator of generic entry), patent claim types, annual sales, patent expirations, failure to pay maintenance fees, ex parte and inter partes reexamination, interference, and disclaimers. Complete details are provided for all FDA-approved small molecule drugs. Annual sales information is available for top-selling drugs. This value-added information supports the critical business functions of patent agents and attorneys, pharmaceutical companies, wholesalers, healthcare payers, and investors.
The Basic Plan provides comprehensive information on all FDA-approved pharmaceutical drugs - discontinued and active, with and without patent protection or other forms of market exclusivity.
The basic plan is simpler than the Premium Plan and Ultimate Plan, lacking the rich graphs, historical archives, sales data, and some of the more powerful search functions. Information on failure to pay patent maintenance fees, reexaminations, interferences, disclaimers, Paragraph IV challenges, and advanced search functions are also not included in the Basic Plan.
The Basic Plan is designed to answer the following questions:
- Which patents cover specific pharmaceutical drugs?
- When do key pharmaceutical drug patents expire?
- Which FDA market exclusivities protect drugs?
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Also available
DrugPatentWatch Premium Plan
DrugPatentWatch Ultimate Plan
Customers who bought this item also bought
DrugPatentWatch Ultimate Plan
DrugPatentWatch Premium Plan
Patent Strategies - Effective Strategies for Extension of Product Lifecycles and Combating Aggressive Generics Markets
GenericHandbook - A Guide to the Generic Drug Industry in the US - 3rd Edition
Patent Expiry Strategies of Big Pharma
Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues
Drug Patent Review and Outlook 2010
Combating Generics: Counter-Generics Strategy, Tactics and Execution
Countering Generic and Biosimilar Threats
Licensing Opportunities: Neurology
|
|
|
|
